Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 112

Sort by

Sort Order Select

Journal Articles

Prophylactic tocilizumab in Relapsed/Refractory multiple myeloma patients treated with bispecific antibodies: A single centre experience

Valeria Ruocco, Luca Vavolo, Tamara Berno, valeria carabotta, Xing Hu, Luca Massarotti, Andrea Serafin, Ivan Zatta, Carmela Gurrieri, Federica Lessi, Livio Trentin, Renato Zambello, Laura Pavan

Blood (2025) 146 (Supplement 1): 7582.

https://doi.org/10.1182/blood-2025-7582

Published: 2025

Journal Articles

Daratumumab, bortezomib, thalidomide and dexamethasone improves renal outcomes in multiple myeloma transplant eligible patients presenting with renal failure: A real life experience from northeastern Italy

Laura Pavan, Valeria Ruocco, Tamara Berno, valeria carabotta, Xing Hu, Luca Massarotti, Luca Vavolo, Ivan Zatta, Gregorio Barila, Edoardo Scomazzon, Anna Furlan, Massimiliano Arangio Febbo, Cristina Clissa, Rossella Paolini, Elena De March, Eugenio Sbisà, Manuela Caizzi, Livio Trentin, Renato Zambello

Blood (2025) 146 (Supplement 1): 2285.

https://doi.org/10.1182/blood-2025-2285

Published: 2025

Journal Articles

The treatment of transplant eligible primary plasmacell leukemia patients: An italian real-life Study

Blood (2025) 146 (Supplement 1): 3977.

https://doi.org/10.1182/blood-2025-3977

Published: 2025

Journal Articles

MiR-146b restoration in T-large granular lymphocyte leukemia: Molecular insights for a new therapeutic strategy

Antonella Teramo, Elisa Rampazzo, Eleonora Roncaglia, Barbara Mariotti, Giulia Calabretto, Elena Buson, Enrico Gaffo, Silvia Orsi, Rebecca Crivellari, Giulia Pertile, Valentina Trimarco, Monica Facco, Flavia Bazzoni, Livio Trentin, Gianpietro Semenzato, Renato Zambello, Stefania Bortoluzzi

Blood (2025) 146 (Supplement 1): 2538.

https://doi.org/10.1182/blood-2025-2538

Published: 2025

Journal Articles

The treatment of patients primary refractory or with sub-optimal response to d-VTD induction: An italian real-life Study

Blood (2025) 146 (Supplement 1): 6363.

https://doi.org/10.1182/blood-2025-6363

Published: 2025

Journal Articles

Bortezomib-melphalan-prednisone (VMP) +/- daratumumab (DVMP) vs. lenalidomide-dexamethasone (Rd) +/- daratumumab (DRd) in transplant-ineligible real-life multiple myeloma patients: Results from the randomized phase IV real MM trial

Blood (2025) 146 (Supplement 1): 6356.

https://doi.org/10.1182/blood-2025-6356

Published: 2025

Journal Articles

Activating STAT3 Mutations Drive CD38 Expression in T-Large Granular Lymphocytic Leukemia

Blood (2024) 144 (Supplement 1): 4132.

https://doi.org/10.1182/blood-2024-210469

Published: 2024

Journal Articles

Consolidation Treatment with VRD Followed By Maintenance with Lenalidomide in Multiple Myeloma Improves Overall Survival: Long-Term Follow-up of the EMN02/HOVON95 Randomized Phase 3 Trial

Blood (2024) 144 (Supplement 1): 674.

https://doi.org/10.1182/blood-2024-197908

Published: 2024

Journal Articles

Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) As Salvage Therapy for Patients with Multiple Myeloma: Multicenter, Retrospective Clinical Experience with 262 Cases Outside of Controlled Clinical Trials

Enrica Antonia Martino, Daniele Derudas, Elena Rossi, Sofia Terlizzi, Giovanni Reddiconto, Paola Stefanoni, Jacopo Micozzi, Silvia Mangiacavalli, Elena Zamagni, Massimo Offidani, Anna Furlan, Gabriele Buda, Sr., Flavia Lotti, Carmine Liberatore, Antonio Lazzaro, Roberta Della Pepa, Giuseppe Bertuglia, Emiliano Barbieri, Concetta Conticello, Claudio De Magistris, Lorenzo De Paoli, Velia Bongarzoni, Anna Maria Cafro, Anna Mele, Pietro Benvenuti, Claudio Cerchione, Cirino Botta, Elisabetta Antonioli, Nicola Sgherza, Sara Aquino, Giuseppe Mele, Gregorio Barila, Salvatore Palmieri, Ombretta Annibali, Rosario Bianco, Massimiliano Arangio Febbo, Gloria Margiotta Casaluci, Angela Rago, Raffaele Fontana, Francesca Farina, Ernesto Vigna, Antonella Bruzzese, Catello Califano, Angela Amendola, Daniela Roccotelli, Alessandra Lombardo, Annalisa Citro, Giuseppina Uccello, Renato Zambello, Alessandro Maggi, Santo Neri, Michele Monachesi, Alessandro Gozzetti, Vittorio Montefusco, Marino Brunori, Nicola Di Renzo, Marta Coscia, Valerio De Stefano, Antonino Neri, Francesco Di Raimondo, Fortunato Morabito, Pellegrino Musto, Massimo Gentile

Blood (2024) 144 (Supplement 1): 4699.

https://doi.org/10.1182/blood-2024-206008

Published: 2024

Journal Articles

Predictors of unsustained measurable residual disease negativity in patients with multiple myeloma

Blood (2024) 143 (7): 592–596.

https://doi.org/10.1182/blood.2023022080

Published: 2024

Includes: Supplemental data

Journal Articles

Combined Inhibition of Protein Kinase CSNK2 and BET Proteins As a Novel Therapeutic Strategy for Mantle Cell Lymphoma

Sabrina Manni, Lara Saggin, Maria Pesavento, Anna Fregnani, Laura Quotti Tubi, Nicolò Danesin, Greta Scapinello, Andrea Visentin, Renato Zambello, Fabrizio Vianello, Livio Trentin, Francesco Piazza

Blood (2023) 142 (Supplement 1): 5778.

https://doi.org/10.1182/blood-2023-182108

Published: 2023

Journal Articles

Lenalidomide Maintenance after VTD Induction and Autologous Stem Cell Transplantation: An Italian Real-Life Study of 558 Patients

Blood (2023) 142 (Supplement 1): 1959.

https://doi.org/10.1182/blood-2023-179922

Published: 2023

Journal Articles

The Use of Next Generation Flow in Multiple Myeloma Patients: A Preliminary Real-Life Multicenter MRD Harmonization Experience

Blood (2023) 142 (Supplement 1): 7161.

https://doi.org/10.1182/blood-2023-186536

Published: 2023

Journal Articles

Salvage Autologous Stem Cell Transplant for the Treatment of First Relapse Multiple Myeloma: Evidence of Its Clinical Role from a Multicenter Italian Study

Blood (2023) 142 (Supplement 1): 2226.

https://doi.org/10.1182/blood-2023-181233

Published: 2023

Journal Articles

Tγδ LGLL identifies a subset with more symptomatic disease: analysis of an international cohort of 137 patients

Blood (2023) 141 (9): 1036–1046.

https://doi.org/10.1182/blood.2021013489

Published: 2023

Includes: Supplemental data

Journal Articles

A Comprehensive, Multiomics Analysis of Natural Killer-Cell Malignancies

Petra Johanna Nygren, Aino Häkkinen, Daehong Kim, Timo Jarvinen, Fumihiro Ishida, Stefania Bortoluzzi, Andrea Binatti, Vanessa Rebecca Gasparini, Renato Zambello, Mikko Myllymäki, Seishi Ogawa, Yusuke Okuno, Hiroshi Kimura, John Chan, Olli Dufva, Satu Mustjoki, Matti Kankainen

Blood (2022) 140 (Supplement 1): 6390–6391.

https://doi.org/10.1182/blood-2022-162285

Published: 2022

Journal Articles

DR-01, a Non-Fucosylated Anti-CD94 Antibody, Depletes Leukemic Cells in Ex Vivo and In Vivo Models of Large Granular Lymphocyte Leukemia

Kelly Shi, Cindy Tan, Lu Bai, Jennifer Richardson, Andy Deng, Matthias Will, Michael Brehm, Dale Greiner, Leonard Shultz, Antonella Teramo, Renato Zambello, David J Feith, Thomas P. Loughran, Jr., Nenad Tomasevic

Blood (2022) 140 (Supplement 1): 2259–2260.

https://doi.org/10.1182/blood-2022-159242

Published: 2022

Journal Articles

Bortezomib-Melphalan-Prednisone (VMP) Vs. Lenalidomide-Dexamethasone (Rd) in Transplant-Ineligible Real-Life Multiple Myeloma Patients: Updated Results of the Randomized Phase IV Real MM Trial

Blood (2022) 140 (Supplement 1): 1814–1816.

https://doi.org/10.1182/blood-2022-162178

Published: 2022

Journal Articles

Interrogating molecular genetics to refine LGLL classification

Gianpietro Semenzato, Renato Zambello

Blood (2022) 139 (20): 3002–3004.

https://doi.org/10.1182/blood.2021015301

Published: 2022

Journal Articles

Rituximab Plus Bendamustine and Cytarabine (R-BAC) in Elderly Patients with Newly Diagnosed Mantle Cell Lymphoma: Long Term Follow-up and Mrd Results of a Phase 2 Study from the Fondazione Italiana Linfomi

Blood (2021) 138 (Supplement 1): 384.

https://doi.org/10.1182/blood-2021-153364

Published: 2021

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Prophylactic tocilizumab in Relapsed/Refractory multiple myeloma patients treated with bispecific antibodies: A single centre experience

Daratumumab, bortezomib, thalidomide and dexamethasone improves renal outcomes in multiple myeloma transplant eligible patients presenting with renal failure: A real life experience from northeastern Italy

The treatment of transplant eligible primary plasmacell leukemia patients: An italian real-life Study

MiR-146b restoration in T-large granular lymphocyte leukemia: Molecular insights for a new therapeutic strategy

The treatment of patients primary refractory or with sub-optimal response to d-VTD induction: An italian real-life Study

Bortezomib-melphalan-prednisone (VMP) +/- daratumumab (DVMP) vs. lenalidomide-dexamethasone (Rd) +/- daratumumab (DRd) in transplant-ineligible real-life multiple myeloma patients: Results from the randomized phase IV real MM trial

Activating STAT3 Mutations Drive CD38 Expression in T-Large Granular Lymphocytic Leukemia

Consolidation Treatment with VRD Followed By Maintenance with Lenalidomide in Multiple Myeloma Improves Overall Survival: Long-Term Follow-up of the EMN02/HOVON95 Randomized Phase 3 Trial

Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) As Salvage Therapy for Patients with Multiple Myeloma: Multicenter, Retrospective Clinical Experience with 262 Cases Outside of Controlled Clinical Trials

Predictors of unsustained measurable residual disease negativity in patients with multiple myeloma

Combined Inhibition of Protein Kinase CSNK2 and BET Proteins As a Novel Therapeutic Strategy for Mantle Cell Lymphoma

Lenalidomide Maintenance after VTD Induction and Autologous Stem Cell Transplantation: An Italian Real-Life Study of 558 Patients

The Use of Next Generation Flow in Multiple Myeloma Patients: A Preliminary Real-Life Multicenter MRD Harmonization Experience

Salvage Autologous Stem Cell Transplant for the Treatment of First Relapse Multiple Myeloma: Evidence of Its Clinical Role from a Multicenter Italian Study

Tγδ LGLL identifies a subset with more symptomatic disease: analysis of an international cohort of 137 patients

A Comprehensive, Multiomics Analysis of Natural Killer-Cell Malignancies

DR-01, a Non-Fucosylated Anti-CD94 Antibody, Depletes Leukemic Cells in Ex Vivo and In Vivo Models of Large Granular Lymphocyte Leukemia

Bortezomib-Melphalan-Prednisone (VMP) Vs. Lenalidomide-Dexamethasone (Rd) in Transplant-Ineligible Real-Life Multiple Myeloma Patients: Updated Results of the Randomized Phase IV Real MM Trial

Interrogating molecular genetics to refine LGLL classification

Rituximab Plus Bendamustine and Cytarabine (R-BAC) in Elderly Patients with Newly Diagnosed Mantle Cell Lymphoma: Long Term Follow-up and Mrd Results of a Phase 2 Study from the Fondazione Italiana Linfomi

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only